WAI YUEN TONG (00897) Reports Interim Results: Net Profit Attributable to Shareholders Drops 88.3% YoY to HK$2.77 Million

Stock News

Nov 24, 2025

WAI YUEN TONG (00897) announced its interim results for the six months ended September 30, 2025. The company recorded revenue of approximately HK$323 million, representing a 6.93% year-on-year decline. Net profit attributable to shareholders was HK$2.77 million, a sharp decrease of 88.3% compared to HK$23.70 million in the same period last year. Earnings per share stood at HK$0.0025.

The company attributed the revenue decline primarily to weaker sales performance in both traditional Chinese medicine and Western medicine/health supplement products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1170823392"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170823392\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170823392?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170823392","market":"sg","top_or_hot":-1,"title":"WAI YUEN TONG (00897) Reports Interim Results: Net Profit Attributable to Shareholders Drops 88.3% YoY to HK$2.77 Million","media":"Stock News","content":"<p>WAI YUEN TONG (00897) announced its interim results for the six months ended September 30, 2025. The company recorded revenue of approximately HK$323 million, representing a 6.93% year-on-year decline. Net profit attributable to shareholders was HK$2.77 million, a sharp decrease of 88.3% compared to HK$23.70 million in the same period last year. Earnings per share stood at HK$0.0025.</p>\n<p>The company attributed the revenue decline primarily to weaker sales performance in both traditional Chinese medicine and Western medicine/health supplement products.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WAI YUEN TONG (00897) Reports Interim Results: Net Profit Attributable to Shareholders Drops 88.3% YoY to HK$2.77 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWAI YUEN TONG (00897) Reports Interim Results: Net Profit Attributable to Shareholders Drops 88.3% YoY to HK$2.77 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-24 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WAI YUEN TONG (00897) announced its interim results for the six months ended September 30, 2025. The company recorded revenue of approximately HK$323 million, representing a 6.93% year-on-year decline. Net profit attributable to shareholders was HK$2.77 million, a sharp decrease of 88.3% compared to HK$23.70 million in the same period last year. Earnings per share stood at HK$0.0025.</p>\n<p>The company attributed the revenue decline primarily to weaker sales performance in both traditional Chinese medicine and Western medicine/health supplement products.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1170823392","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170823392","pubTimestamp":1763995112,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"WAI YUEN TONG (00897) announced its interim results for the six months ended September 30, 2025. The company recorded revenue of approximately HK$323 million, representing a 6.93% year-on-year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00897":"位元堂"},"translate_title":"位元堂(00897)公布中期业绩：股东应占纯利同比降88.3%至277万港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00897":1},"content_text":"WAI YUEN TONG (00897) announced its interim results for the six months ended September 30, 2025. The company recorded revenue of approximately HK$323 million, representing a 6.93% year-on-year decline. Net profit attributable to shareholders was HK$2.77 million, a sharp decrease of 88.3% compared to HK$23.70 million in the same period last year. Earnings per share stood at HK$0.0025.\nThe company attributed the revenue decline primarily to weaker sales performance in both traditional Chinese medicine and Western medicine/health supplement products.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}